PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges.
With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide.
The Subcutaneous DMPA Access Collaborative is a project funded by the Bill and Melinda Gates Foundation and the Children’s Investment Fund Foundation and led by PATH in collaboration with John Snow, Incorporated (JSI).
Subcutaneous DMPA is an innovative subcutaneous contraceptive that is progressively being introduced in many countries. The Access Collaborative project facilitates global coordination of supply planning and introduction and scale up efforts in priority countries.
The project helps plan, coordinate, and monitor the introduction and scale-up efforts in seven priority geographies and shares lessons learned, best practices, and other relevant information regionally and globally through technical assistance and a Learning and Action Network.
PATH SENEGAL is hiring a fixed-term employee to reinforce the Subcutaneous DMPA Access Collaborative team in Senegal to plan, implement and evaluate a family planning e-learning training module for health care providers in five regions of Senegal.
The Program Officer will work closely with representatives of the MOH’s Direction of Maternal and Child Health (DSME) and the PATH team to plan and coordinate activities including post-training supervision visits and collection and analysis of evaluation data.
The position is expected to remain active through July 2020.
DMPA-SC (brand name Sayana Press) is a subcutaneous injectable contraceptive that is currently available throughout Senegal, and is a safe, effective, reversible, and discreet method to prevent pregnancy.
It contains a single dose of depot medroxyprogesterone acetate (commonly known by the brand name Depo-Provera®) that is formulated for subcutaneous administration with the easy-to-use, pre-filled Uniject™ injection system.
Clients can be trained to self-inject, and training of providers to counsel and supervise self-injection clients has begun to roll out in nine of Senegal’s 14 regions.